MedPath

Evaluation of Heidelberg Engineering SPECTRALIS With OCT Angiography Module

Not Applicable
Completed
Conditions
Normal Eyes
Retinal Vascular
Interventions
Device: OCT Angiography
Device: Color Fundus Photography
Device: Fluorescein Angiography
Device: Indocyaine Green Angiography
Registration Number
NCT03279939
Lead Sponsor
Heidelberg Engineering GmbH
Brief Summary

Assessment of image quality and clinical relevance of OCT Angiography via comparison to FA/ICGA.

Detailed Description

The objectives of this study are:

1. To compare the OCTA image quality between the SPECTRALIS and the predicate.

2. To compare the agreement of clinical findings on SPECTRALIS OCTA to the predicate.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
95
Inclusion Criteria

All subjects:

  • Able and willing to undergo the test procedures, sign informed consent, and follow instructions.
  • Age ≥ 22

Subjects with Normal Eyes:

  • Subjects presenting at the site without uncontrolled systemic conditions, or ocular disease, as determined by the Investigator
  • Corrected visual acuity ≥ 20/40 in each eye
  • No history of ocular surgical intervention (except for refractive or cataract surgery) in either eye

Subjects with Pathology:

  • Subjects with retinal conditions in at least one eye.
  • Subjects included can have a range of retinal vascular pathologies affecting different anatomic depths through the retina and choroid. Retinal conditions including but not limited to diabetic retinopathy, wet age-related macular degeneration (AMD), and branch or central retinal vein occlusion that give rise to features such as retinal ischemia, microaneurysms, choroidal neovascularization and retinal neovascularization will be included.
Exclusion Criteria
  • Subjects unable to read or write
  • Subjects with ocular media not sufficiently clear to obtain acceptable study-related imaging
  • Subjects who cannot tolerate the imaging procedures
  • Subjects with known allergies to fluorescein dye, Indocyanine Green (ICG), shellfish, drugs for pupillary dilation
  • Subjects with contraindication to pupillary dilation in study eye

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Subjects with Normal EyesColor Fundus PhotographyOCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
Subjects with Normal EyesFluorescein AngiographyOCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
Subjects with PathologyOCT AngiographyOCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
Subjects with PathologyColor Fundus PhotographyOCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
Subjects with PathologyIndocyaine Green AngiographyOCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
Subjects with Normal EyesOCT AngiographyOCT Angiography, Color Fundus Photography, and Fluorescein Angiography as per protocol in subjects without ophthalmic pathology.
Subjects with PathologyFluorescein AngiographyOCT Angiography, Color Fundus Photography, Fluorescein Angiography, and when clinically indicated, Indocyaine Green Angiography as per protocol in subjects with retinal vascular pathology.
Primary Outcome Measures
NameTimeMethod
Clinically relevant findings on OCTAday 1

Clinically relevant grading results of study selected images

OCTA image qualityday 1

Image quality grading results of study selected images

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Retina Consultants of Houston

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath